KellyJ., CainsG., RailingsM., GilmoreS.Safety and Efficacy of Mometasone Furoate Cream in the Treatment of Steroid Responsive Dermatoses.Australas J. Dermatol1991; 32: 85–91.
2.
RosenthalD., DukeE.A Clinical Investigation of the Efficacy and Safety of Mometasone Furoate Ointment 0.1% vs. Betamethasone Valerate Ointment 0.1% in the Treatment of Psoriasis.Current Therapeutic Research1988; 44(5): 790–801.
3.
VigliogliaP., JonesM.L., PeetsE.A.. Once -daily 0.1% Mometasone Furoate Cream versus Twice-daily 0.1% Betamethasone Valerate Cream in the Treatment of a Variety of Dermatoses.J International Medical Research1990; 18: 460–67.
4.
LebwohlM., PeetsE., ChenV.Limited Application of Mometasone Furoate on the Face and Intertriginous Areas: Analysis of Safety and Efficacy.Intl J of Dermatol1993; 32: 830–31.
5.
BraschJ.The atrophogenic potential of mometasone furoate in a clinical long-term study.Z Hautkr1991; 66: 785–87.
6.
KatzH., PrawerS., WatsonM., ScullT., PeetsE.Mometasone Furoate Ointment 0.1% vs. Hydrocortisone Ointment 1.0% in Psoriasis.Intl J of Dermatol; June1989; 28: 342–344.
7.
BressinckR., WilliamsJ., PeetsE.Comparison of the Effect of Mometasone Furoate Ointment 0.1%, and Hydrocortisone Ointment 1%, on Adrenocortical Function in Psoriasis Patients.Today's Therapeutic Trends1988; 5: 25–35.
8.
VernonH., LaneA., WestonW.Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis.JAAD1991; 24: 603–07.
9.
CallenJ.Comparison of Safety and Efficacy of Fluticasone Propionate Cream, 0.05%, and Betamethasone Valerate Cream, 0.1%, in the Treatment of Moderate-to-Severe Psoriasis.Cutis1996; 57(2S): 37–42.
10.
RobertsD.Comparison of Fluticasone Propionate Ointment, 0.005%, and Betamethasone-17, 21-Dipropionate Ointment, 0.05%, in the Treatment of Psoriasis.Cutis1996; 57(2S): 19–23.
11.
KecskesA., Heger-MahnD., KuhlmannK., LangeL.Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal anti-inflammatory activity.JAAD1993; 29: 576–80.
12.
DiPetrilloT., LeeH., CutroneoK.Anti-inflammatory Adrenal Steroids that Neither Inhibit Skin Collagen Synthesis nor Cause Dermal Atrophy.Arch Dermatol1984; 120: 878–83.
13.
MillsC.M., MarksR.Side Effects of Topical Glucocorticoids.Curr Probl Dermatol1993; 21: 122–31.
14.
KortingH.C., VielufD., KerscherM.0.25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% Betamethasone-17 valerate cream and 0.05% Clobetasol-17 propionate cream.Eur J Clin Pharmacol1992; 42: 159–161.
15.
KerscherM.J., KortingH.C.. Topical Glucocorticoids of the Non-fluorinated Double-ester Type.Acta Derm Venereol1992; 72: 214–16.
16.
Schafer-KortingM., KortingH., KerscherM., LenhardS.Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.Clin Pharmacol Therapeutics1993; 54: 448–56.
